Triple Negative Breast Neoplasms: all 1,163 studies

Page 5 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast CancerRecruitingNCT04959474Not applicable
• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICIRecruitingNCT04954599Phase 1/2
• Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast CancerRecruitingNCT04947189Phase 1/2
• A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast CancerRecruitingNCT04914390Phase 2
• Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04907344Phase 2/3
• A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsRecruitingNCT04895709Phase 1/2
• Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)RecruitingNCT04861077Early Phase 1
• Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Phase 4
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067RecruitingNCT04787042Phase 1/2
• MicroRNA Profiles in Triple Negative Breast CancerRecruitingNCT04771871Phase 2
• Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast CancerRecruitingNCT04768426Phase 2
• Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast CancerRecruitingNCT04739670Phase 2
• Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast CancerRecruitingNCT04722978Phase 3
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerRecruitingNCT04683679Phase 2
• Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient PatientsRecruitingNCT04677816Phase 2
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)RecruitingNCT04585750Phase 1/2
• A Multicenter Cancer Biospecimen Collection StudyRecruitingNCT04510129
• A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBCRecruitingNCT04501523Phase 2
• A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative BreastRecruitingNCT04481763Phase 1/2
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCRecruitingNCT04468061Phase 2
• Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT04437160Phase 2
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2
• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerRecruitingNCT04348747Phase 2
• to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04301739Phase 3
• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
• Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid MalignanciesRecruitingNCT04282044Phase 1
• Sacituzumab Govitecan In TNBCRecruitingNCT04230109Phase 2
• Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant ChemotherapyNot yet recruitingNCT04225858Not applicable
• Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) PatientsRecruitingNCT04159818Phase 2
• Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast CancerRecruitingNCT04159142Phase 2
• Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast CancerRecruitingNCT04138719Phase 2
• Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCTRecruitingNCT04137653Phase 3
• Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast CancerRecruitingNCT04136782Phase 4
• Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast CancerRecruitingNCT03920488
• Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseaseRecruitingNCT03808337Phase 2
• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2
• A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer PatientsRecruitingNCT03671044Phase 3
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingNCT03606967Phase 2
• A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
• Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)RecruitingNCT03017573Not applicable
• Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic TherapyRecruitingNCT02945579Not applicable
• Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast CancerRecruitingNCT02926690Phase 1
• Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.Not yet recruitingNCT02802423Phase 1/2
• Huaier Granule in Treating Women With Triple Negative Breast CancerRecruitingNCT02615457Phase 4
• PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line ChemotherapyNot yet recruitingNCT02448576Not applicable
• Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier RegistryRecruitingNCT02302742
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast CancerTerminatedNCT05756166Phase 1/2Results posted
• NUC-3373 in Combination With Other Agents in Patients With Advanced Solid TumoursTerminatedNCT05714553Phase 1/2Results posted
• A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)Active, not recruitingNCT05460273Phase 1/2Results posted
• A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerTerminatedNCT05451849Phase 1/2Results posted
• Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTerminatedNCT05113966Phase 2Results posted
• Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerCompletedNCT05112536Phase 2Results posted
• T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial CancersTerminatedNCT05035407Phase 1Results posted
• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results posted
• A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid TumorsCompletedNCT05001347Phase 2Results posted
• Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerTerminatedNCT04958785Phase 2Results posted
• A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesTerminatedNCT04927884Phase 1/2Results posted
• A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedNCT04916002Phase 2Results posted
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular DiseaseActive, not recruitingNCT04915755Phase 3Results posted
• A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersCompletedNCT04879849Phase 1Results posted
• Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerTerminatedNCT04849364Phase 2Results posted
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedNCT04789668Phase 1/2Results posted
• Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX TherapyTerminatedNCT04770272Phase 2Results posted
• Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast CancerCompletedNCT04758780Phase 2Results posted
• A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerCompletedNCT04699630Phase 2Results posted
• A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerTerminatedNCT04690855Phase 2Results posted
• Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast CancerCompletedNCT04674306Early Phase 1Results posted
• A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT04577963Phase 1/2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)TerminatedNCT04504916Phase 2Results posted
• Palbociclib and Binimetinib in Advanced Triple Negative Breast CancerCompletedNCT04494958Phase 1/2Results posted
• Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast CancerTerminatedNCT04489940Phase 2Results posted
• A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast CancerTerminatedNCT04461600Phase 2Results posted
• A Study of NM21-1480 in Adult Patients With Advanced Solid TumorsTerminatedNCT04442126Phase 1/2Results posted
• A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid TumorsTerminatedNCT04424641Phase 1/2Results posted
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingNCT04345913Phase 1/2Results posted
• NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT04332653Phase 1/2Results posted
• Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast CancerTerminatedNCT04331067Phase 1/2Results posted
• BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)TerminatedNCT04296942Phase 1Results posted
• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN LossTerminatedNCT04251533Phase 3Results posted
• Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsTerminatedNCT04234113Phase 1Results posted
• A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Active, not recruitingNCT04225117Phase 2Results posted
• Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN AlterationsTerminatedNCT04216472Phase 2Results posted
• Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)TerminatedNCT04191135Phase 2Results posted
• A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT04177108Phase 3Results posted
• A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast CancerCompletedNCT04148911Phase 3Results posted
• Sitravatinib in Metastatic Breast CancerTerminatedNCT04123704Phase 2Results posted
• Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast CancerCompletedNCT04111510Phase 2Results posted
• A Study of LY3435151 in Participants With Solid TumorsTerminatedNCT04099277Phase 1Results posted
• Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast CancerTerminatedNCT04095689Phase 2Results posted
• Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast CancerCompletedNCT04081389Phase 1Results posted
• LY3023414 and Prexasertib in Metastatic Triple-negative Breast CancerCompletedNCT04032080Phase 2Results posted
• A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)TerminatedNCT03992131Phase 1/2Results posted
• Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT03941730Phase 2Results posted
• A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast CancerTerminatedNCT03901469Phase 2Results posted
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid TumorsTerminatedNCT03875313Phase 1/2Results posted
• Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant ChemotherapyTerminatedNCT03872388Phase 2Results posted
• Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast CancerCompletedNCT03853707Phase 1/2Results posted
• Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCTerminatedNCT03838367Phase 1/2Results posted

← Triple Negative Breast Neoplasms overview